Evidence map›Paper›PMID 31029560›Full record

Trial reportEuropean urology focus2019

Phase III Trial of Intravenous Mannitol Versus Placebo During Nephron-sparing Surgery: Post Hoc Analysis of 3-yr Outcomes.

Nathan C Wong, Ricardo G Alvim, Daniel D Sjoberg, Roman Shingarev, Nicholas E Power, Massimiliano Spaliviero, Katie S Murray, Nicole E Benfante, A Ari Hakimi, Paul Russo and 1 more

Open access · greenAbstract readClinical Trial, Phase IIIComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European urology focus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Nathan C WongUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ricardo G AlvimUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel D SjobergDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Roman ShingarevRenal Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicholas E PowerDivision of Urology, Western University, London, ON, Canada.
Massimiliano SpalivieroStony Brook Medicine, SUNY at Stony Brook, Stony Brook, NY, USA.
Katie S MurrayDepartment of Surgery, Division of Urology, University of Missouri, Columbia, MO, USA.
Nicole E BenfanteSloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul RussoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: colemanj@mskcc.org.
Memorial Sloan Kettering Cancer Center · USStony Brook Medicine · USUniversity of Missouri · USWestern University · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Our recently reported phase III trial demonstrated that patients undergoing nephron-sparing surgery (NSS) with an estimated glomerular filtration rate (eGFR) of ≥45 ml/min/1.73 m

Indexed as

ComorbidityDiuretics, OsmoticGlomerular Filtration RateHumansIntraoperative CareKidney NeoplasmsMannitolNephrectomyNephronsOrgan Sparing TreatmentsOutcome Assessment, Health CarePlacebosPostoperative PeriodPreoperative PeriodDiuretics, OsmoticMannitolPlacebosfunctionMannitolNephron-sparing surgeryPartial nephrectomyRenal

Identifiers

PMID31029560
PMCPMC8560079
OpenAlexW2940849032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.